pentobarbital will lower the extent or outcome of atogepant by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep an eye on Closely. Recommended atogepant dosage with concomitant utilization of robust or moderate CYP3A4 inducers is 30 mg or sixty mg qDay.Reserve concomitant prescribing of such drugs in individuals for whom o